ERBB2 and neoplasm: We show that the combined treatment with WIP1 and miR-21 inhibitors using the nanoparticle significantly reduces trastuzumab-resistant HER2+ tumor growth, confirming that co-inhibition of WIP1 and miR-21 is a promising therapeutic strategy.